Review
Copyright ©The Author(s) 2022.
World J Gastroenterol. Oct 7, 2022; 28(37): 5403-5419
Published online Oct 7, 2022. doi: 10.3748/wjg.v28.i37.5403
Table 4 Overview of Immunotherapy-based novel nanoparticles in the treatment of pancreatic cancer [PubMed Search (immunotherapy) AND (nanoparticle) AND (pancreatic cancer)]
Type of nanoparticle
Treatment strategy
Drugs or active substance involved
The main involvement of immune cells
Ref.
Clustered nanoparticleICIs, TGF-β receptor inhibitorsLY2157299, siPD-L1T cellsWang et al[133]
HAS-LiposomesICD, ICIs, PTTBMS-202, IR780DCs, CTLs, T cellsYu et al[134]
CopolymersICIssiPD-L1CD8+T cells, NK cellsJung et al[138]
LNPsSTING and TLR4 therapySTING agonist, R4 agonistDCs, Tregs, TAMsLorkowski et al[139]
Micellar nanoparticleInhibit G-MDSCs recruitment, chemotherapyLMWH, PTXG-MDSC, CD8+T cells, CD4+T cellsLu et al[142]
UCNPsPyroptosisK3ZrF7:Yb/Er UCNPsDCs, memory T cellsDing et al[148]
Cancer cell membrane with copolymersICIs, M2-macrophages targetingM2pep, TAAs, PD-L1 antibodyTAMs, CD8+T cellsWang et al[151]
PDSA-based nanoplatformSuppression of FFAs, repolarization of TAMssiMGLL, siCB-2TAMsCao et al[152]
CopolymersPTT, immunotherapyICG, IMQ, IONsTAMs, CD8+T cells, CD4+T cells, CD4+T cellsWang et al[153]
IONsRepolarization of TAMsFerumoxytolTAMsZanganeh et al[154]